The aim of this study was to describe t he clinicopathologic features and prognosis of endometrial cancer patients diag-nosed during or after tamoxifen treatment for breast cancer.Fifty -six tamoxifen -related endom e...The aim of this study was to describe t he clinicopathologic features and prognosis of endometrial cancer patients diag-nosed during or after tamoxifen treatment for breast cancer.Fifty -six tamoxifen -related endom etrial cancers were i-dentified from 10hospitals in Japan.Past users were de-fined as endometrial cancer patient s diagnosed more than12months after the cessation of tamo xifen treatment for breast cancer.All other users were c lassified as recent users.Age at diagnosis of the endome trial cancer ranged from 29to 81years.Sixteen(29%)and 19(34%)pa-tients were nulliparous and overweight,respectively.When the patients were divided into two groups:30recent and 26past users,the distribution of various clinical characteris-tics,except for age at the time of dia gnosis for endometrial cancer and the interval between the d iagnoses of two can-cers,was similar for two groups.The daily dose,duration and cumulative dose also showed no significant difference between the two groups.Past users had histopathologicallymore invasive tumors showing prognostically more unfavor-able subtypes than recent users.The background lesions including endometrial polyps and di ffuse cystic changes were similar for the two groups.The c umulative 3-year survivalwas significantly worse fo r past users than for recent users(74.8%and 96.4%,respectively,P <0.04).In multivariate analysis including re centness of tamoxifen use and age at diagnosis of endometrial cancer,the significance of past user disappeared.Past users had a worse prognosis of endometrial cancer with more inva sive histologic features than recent users,probably because they includedmore elderly patients.展开更多
The risk of tamoxifen related endome trial neoplasm has been confirmed by multiple studies.Especially rare en-dometrial tumors seem to develop more frequently under tamoxifen therapy.A recent analysis showed a substan...The risk of tamoxifen related endome trial neoplasm has been confirmed by multiple studies.Especially rare en-dometrial tumors seem to develop more frequently under tamoxifen therapy.A recent analysis showed a substantially higher risk for malignant mixed meso dermal tumor(MMMT;designated in the WHO classification of female genital tract neoplasms as carcinosarcoma )in association with tamoxifen intake.We are reporting a case of a 40-year -old multiparous premenopausa l woman who received tamoxifen 20mg daily for 2years afte r the surgical treat-ment of breast cancer and subsequent adjuvant chemother-apy.Two years after initiation of ta moxifen treatment,the patient developed anMMMTof the uterus.More than 64months after radical hysterectomy,salpingo -oophorecto-my,and pelvic lymphadenectomy,she remains recur-rence -free for MMMT.Unfortunately,she developed a local recurrence of her breast cancer in 2003.After surgi-cal treatment,she is currently bein g treated with anastro-zole.We are reporting a rare case of a premenopausal pa-tient who developed a MMMT within short time of tamoxifen exposure for stage I breast cancer.展开更多
OBJECTIVE: The use of tamoxifen to prevent breast cancer and decrease recurr en ce is not controversial. However, the effect that tamoxifen may have in women wi th a history of breast cancer in whom endometrial cancer...OBJECTIVE: The use of tamoxifen to prevent breast cancer and decrease recurr en ce is not controversial. However, the effect that tamoxifen may have in women wi th a history of breast cancer in whom endometrial cancer develops is unclear. Th e purpose of this study was to estimate whether a history of tamoxifen use is a prognostic factor for such patients. METHODS: Between 1990 and 2002, patients se en at The University of Texas M. D. Anderson Cancer Center with a history of bre ast cancer who developed endometrial cancer were identified. Medical records wer e reviewed to identify clinical, pathologic, and outcome information. RESULTS: E ighty-nine patients with a history of breast cancer in whom endometrial carcino ma developed were identified. Fifty-two percent (46/89) had a history of tamoxi fen use (median duration 48 months; range 2-120 months). There were no signific ant differences in the clinical or pathologic features between tamoxifen users a nd nonusers. A history of tamoxifen use was associated with a shorter interval f rom breast cancer to endometrial cancer diagnosis (77.2 versus 121.3 months for nonusers; P = .01). There was no significant difference in overall survival betw een tamoxifen users and nonusers (39.2 months versus 48.3 months, P = .27), and there was no difference in endometrial cancer-specific survival duration betwee n tamoxifen users and nonusers (55.7 versus 51.0 months, P = .92). CONCLUSION: A mong tamoxifen users, the interval from breast cancer to endometrial cancer diag nosis was significantly shorter than that in nonusers. In this cohort, a history of tamoxifen use was not associated with a worse overall or disease-specific s urvival.展开更多
目的:评估抗雌激素药它莫西芬和雷洛昔芬在治疗青春期持续性男性乳房发育的效果。研究设计:回顾性研究38例在一个儿童内分泌科就诊的青春期持续性男性乳房发育的患儿。患儿仅得到保证或3-9个月疗程的雌激素受体抑制剂(它莫西芬和雷洛昔...目的:评估抗雌激素药它莫西芬和雷洛昔芬在治疗青春期持续性男性乳房发育的效果。研究设计:回顾性研究38例在一个儿童内分泌科就诊的青春期持续性男性乳房发育的患儿。患儿仅得到保证或3-9个月疗程的雌激素受体抑制剂(它莫西芬和雷洛昔芬)的治疗。结果:患儿平均年龄为14.6岁(s=1.5岁),患男性乳房发育的平均持续时间为28.3月(s=16.4月)。在使用它莫西芬和雷洛西芬后,胸部结节直径平均减少分别为2.1cm(95%CI 1.7-2.7,P【0.0001)和2.5 cm(95% CI 1.7-3.3,P【0.0001)。在使用它莫西芬和雷洛昔芬后,分别可看到86%和91%的患儿得到改善,但是,展开更多
文摘The aim of this study was to describe t he clinicopathologic features and prognosis of endometrial cancer patients diag-nosed during or after tamoxifen treatment for breast cancer.Fifty -six tamoxifen -related endom etrial cancers were i-dentified from 10hospitals in Japan.Past users were de-fined as endometrial cancer patient s diagnosed more than12months after the cessation of tamo xifen treatment for breast cancer.All other users were c lassified as recent users.Age at diagnosis of the endome trial cancer ranged from 29to 81years.Sixteen(29%)and 19(34%)pa-tients were nulliparous and overweight,respectively.When the patients were divided into two groups:30recent and 26past users,the distribution of various clinical characteris-tics,except for age at the time of dia gnosis for endometrial cancer and the interval between the d iagnoses of two can-cers,was similar for two groups.The daily dose,duration and cumulative dose also showed no significant difference between the two groups.Past users had histopathologicallymore invasive tumors showing prognostically more unfavor-able subtypes than recent users.The background lesions including endometrial polyps and di ffuse cystic changes were similar for the two groups.The c umulative 3-year survivalwas significantly worse fo r past users than for recent users(74.8%and 96.4%,respectively,P <0.04).In multivariate analysis including re centness of tamoxifen use and age at diagnosis of endometrial cancer,the significance of past user disappeared.Past users had a worse prognosis of endometrial cancer with more inva sive histologic features than recent users,probably because they includedmore elderly patients.
文摘The risk of tamoxifen related endome trial neoplasm has been confirmed by multiple studies.Especially rare en-dometrial tumors seem to develop more frequently under tamoxifen therapy.A recent analysis showed a substantially higher risk for malignant mixed meso dermal tumor(MMMT;designated in the WHO classification of female genital tract neoplasms as carcinosarcoma )in association with tamoxifen intake.We are reporting a case of a 40-year -old multiparous premenopausa l woman who received tamoxifen 20mg daily for 2years afte r the surgical treat-ment of breast cancer and subsequent adjuvant chemother-apy.Two years after initiation of ta moxifen treatment,the patient developed anMMMTof the uterus.More than 64months after radical hysterectomy,salpingo -oophorecto-my,and pelvic lymphadenectomy,she remains recur-rence -free for MMMT.Unfortunately,she developed a local recurrence of her breast cancer in 2003.After surgi-cal treatment,she is currently bein g treated with anastro-zole.We are reporting a rare case of a premenopausal pa-tient who developed a MMMT within short time of tamoxifen exposure for stage I breast cancer.
文摘OBJECTIVE: The use of tamoxifen to prevent breast cancer and decrease recurr en ce is not controversial. However, the effect that tamoxifen may have in women wi th a history of breast cancer in whom endometrial cancer develops is unclear. Th e purpose of this study was to estimate whether a history of tamoxifen use is a prognostic factor for such patients. METHODS: Between 1990 and 2002, patients se en at The University of Texas M. D. Anderson Cancer Center with a history of bre ast cancer who developed endometrial cancer were identified. Medical records wer e reviewed to identify clinical, pathologic, and outcome information. RESULTS: E ighty-nine patients with a history of breast cancer in whom endometrial carcino ma developed were identified. Fifty-two percent (46/89) had a history of tamoxi fen use (median duration 48 months; range 2-120 months). There were no signific ant differences in the clinical or pathologic features between tamoxifen users a nd nonusers. A history of tamoxifen use was associated with a shorter interval f rom breast cancer to endometrial cancer diagnosis (77.2 versus 121.3 months for nonusers; P = .01). There was no significant difference in overall survival betw een tamoxifen users and nonusers (39.2 months versus 48.3 months, P = .27), and there was no difference in endometrial cancer-specific survival duration betwee n tamoxifen users and nonusers (55.7 versus 51.0 months, P = .92). CONCLUSION: A mong tamoxifen users, the interval from breast cancer to endometrial cancer diag nosis was significantly shorter than that in nonusers. In this cohort, a history of tamoxifen use was not associated with a worse overall or disease-specific s urvival.
文摘目的:评估抗雌激素药它莫西芬和雷洛昔芬在治疗青春期持续性男性乳房发育的效果。研究设计:回顾性研究38例在一个儿童内分泌科就诊的青春期持续性男性乳房发育的患儿。患儿仅得到保证或3-9个月疗程的雌激素受体抑制剂(它莫西芬和雷洛昔芬)的治疗。结果:患儿平均年龄为14.6岁(s=1.5岁),患男性乳房发育的平均持续时间为28.3月(s=16.4月)。在使用它莫西芬和雷洛西芬后,胸部结节直径平均减少分别为2.1cm(95%CI 1.7-2.7,P【0.0001)和2.5 cm(95% CI 1.7-3.3,P【0.0001)。在使用它莫西芬和雷洛昔芬后,分别可看到86%和91%的患儿得到改善,但是,
